Physician profile
Carlos Torrellas
NPI 1245394832
$13,317.77
in general payments reported to CMS, 2019-2025
31 companies · $1,992 in 2025
The $1,992 reported for 2025 was more than what 89% of Psychiatry providers received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,515 · 2020: $1,295 · 2021: $1,935 · 2022: $1,782 · 2023: $2,873 · 2024: $1,926 · 2025: $1,992.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,710 · Education: $80.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,709.83 |
| Education | $80.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $1,656.47 | 2019-2025 | Rexulti, Abilify Asimtufii, Nuedexta |
| Teva Pharmaceuticals USA, INC. | $1,380.22 | 2019-2025 | Austedo Xr, Uzedy, Austedo |
| Vanda Pharmaceuticals INC. | $1,349.52 | 2019-2025 | Fanapt, Hetlioz |
| Janssen Pharmaceuticals, INC | $1,232.11 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Takeda Pharmaceuticals U.S.A., INC. | $1,135.80 | 2019-2025 | Trintellix |
| Abbvie INC. | $966.04 | 2021-2025 | Vraylar |
| Lundbeck LLC | $917.33 | 2019-2025 | Rexulti |
| Alkermes, INC. | $750.72 | 2019-2025 | Aristada, Lybalvi, Vivitrol |
| Neurocrine Biosciences, INC. | $514.56 | 2019-2025 | Ingrezza |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $481.82 | 2020-2025 | Caplyta |
| Axsome Therapeutics, INC. | $384.76 | 2022-2025 | Auvelity |
| Bausch Health US, LLC | $342.04 | 2019-2025 | Aplenzin, Wellbutrin |
| Sunovion Pharmaceuticals INC. | $298.54 | 2019-2020 | |
| Allergan, INC. | $286.84 | 2019-2020 | |
| Almatica Pharma LLC | $267.62 | 2021-2025 | Loreev Xr |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $267.61 | 2022-2023 | Sublocade |
| Avanir Pharmaceuticals, INC. | $264.85 | 2019-2022 | |
| Eisai INC. | $262.51 | 2020-2021 | |
| Idorsia Pharmaceuticals US INC | $170.17 | 2022-2024 | Quviviq |
| Neos Therapeutics, LP | $80.19 | 2020-2024 | Adzenys Xr-Odt |
| Braeburn INC. | $67.66 | 2023-2024 | Brixadi |
| Merck Sharp & Dohme LLC | $48.97 | 2020-2023 | Belsomra |
| Livanova USA, INC. | $30.65 | 2021 | |
| Arbor Pharmaceuticals, INC. | $28.86 | 2019 | |
| Supernus Pharmaceuticals, INC. | $24.70 | 2023 | Qelbree |
| Ironshore Pharmaceuticals INC. | $23.94 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $23.10 | 2025 | Cobenfy |
| Shire North American Group INC | $19.70 | 2019 | |
| Tris Pharma INC | $19.06 | 2023 | Dyanavel Xr |
| Galderma Laboratories, L.P. | $14.35 | 2019 | |
| Neuronetics, INC. | $7.06 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Torrellas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.